Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 4/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.31 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475281 | 1.00 | MEN1 (0.39) | MEN1LMNATHRBBLMKMT2A | |
| Ammonia Solution, Strong SCHEMBL5027961 | 0.98 | MEN1 (0.38) | MEN1LMNATHRBBLMKMT2A | |
| Toluene SCHEMBL27883440 | 0.89 | TSHR (0.38) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL28826844 | 0.84 | XDH (0.43) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL730352 | 0.81 | — | — | |
| SCHEMBL555089 | 0.81 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL731714 | 0.78 | — | — | |
| SCHEMBL2874933 | 0.78 | — | — | |
| SCHEMBL27172104 | 0.78 | — | — | |
| SCHEMBL3146080 | 0.77 | METAP2 (0.31) | MEN1KMT2AALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117448064-A | Conductive lubricant | 甘肃海亮新能源材料有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-116103647-A | Novel blackening liquid medicine and preparation method thereof and conductive film blackening method | 江苏软讯科技有限公司 | 2023-05-12 | — | — | CN | claimed |
| US-9683001-B2 | Process of producing phosphinothricin employing nitrilases | Stragegic Enzyme Applications, Inc. (US) | 2017-06-20 | — | — | US | claimed |
| US-20150239917-A1 | Process of Producing Phosphinothricin Employing Nitrilases | STRATEGIC ENZYME APPLICATIONS, INC. (US) | 2015-08-27 | — | — | US | claimed |
| US-6106599-A | Inks | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | claimed |
| EP-3971201-B1 | CELL CULTURING SCAFFOLD MATERIAL AND CELL CULTURING CONTAINER | SEKISUI CHEMICAL CO LTD (JP) | 2026-01-28 | — | — | EP | disclosed |
| EP-3971200-B1 | CELL CULTURING SCAFFOLDING MATERIAL AND CELL CULTURING VESSEL | SEKISUI CHEMICAL CO LTD (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-12460167-B2 | Scaffold material for cell culture and cell culture container | SEKISUI CHEMICAL CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| US-12365860-B2 | Scaffolding material for stem cell cultures and stem cell culture method using same | SEKISUI CHEMICAL CO., LTD. (JP) | 2025-07-22 | — | — | US | disclosed |
| EP-4580638-A1 | CHEMICAL CONJUGATES, COMPOSITIONS, AND METHODS OF PREPARATION AND USE THEREOF | Transfection Holdings Limited (NZ) | 2025-07-09 | — | — | EP | disclosed |
| CN-111511895-B | Scaffold material for stem cell culture and stem cell culture method using same | 积水化学工业株式会社 | 2025-05-13 | — | — | CN | disclosed |
| CN-111511896-B | Scaffold material for stem cell culture and stem cell culture method using same | 积水化学工业株式会社 | 2025-05-13 | — | — | CN | disclosed |
| EP-1181288-A1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-27 | — | — | EP | disclosed |
| US-20010041728-A1 | Oxazolidinone antibacterial agents having a thiocarbonyl functionality | HESTER JACKSON B (US) | 2001-11-15 | — | — | US | disclosed |
| WO-2001077650-A1 | ANALYTE DETECTION & APPARATUS THEREFOR | UNIVERSITY OF STRATHCLYDE (GB) | 2001-10-18 | — | — | WO | disclosed |
| EP-1133493-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000073284-A2 | 1,4-BENZODIAZEPIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000073301-A1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2000-12-07 | — | — | WO | disclosed |
| US-6106599-A | Inks | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | disclosed |
| WO-2000032599-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041728-A1 | Oxazolidinone antibacterial agents having a thiocarbonyl functionality | OXA1L, MRPL21, TOP1 | MEN1 2314/4885LMNA 4694/4885THRB 2785/4885 |
| US-20150239917-A1 | Process of Producing Phosphinothricin Employing Nitrilases | NPEPPS, NISCH, NAAA | MEN1 910/4885LMNA 4719/4885THRB 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.